Alizé Pharma launches Phase II clinical trial of AZP-531 in Prader-Willi syndrome

05-Mar-2015 - Alizé Pharma announced the launch of a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, in patients with Prader-Willi syndrome.The trial is a randomized, double blind and placebo controlled study. It aims to evaluate the safety and effects of a two-week treatment with AZP-531 ...

Alize Pharma launches the PREMAG research program

11-Jan-2013 - Alize Pharmaannounces the launch of the PREMAG collaborative research program. This program will be conducted within a consortium of partners focusing on the development of AZP-531, Alize Pharma’s unacylated ghrelin analog and biomarkers; for therapeutic applications in muscular protection and ...

Alize Pharma closes EUR 3.3 million funding round

07-Jun-2012 - Alize Pharma announced that it has completed a funding round of EUR 3.3 million. The funds will allow to take AZP-531, its UAG (UnAcylated Ghrelin) analog, into Phase I clinical trials.Alize Pharma will carry out the first (Phase I) clinical trial of AZP-531 in healthy volunteers in 2013, which ...

Alizé Pharma signs research collaboration and license option agreement with Lilly

Companies to collaborate on an exclusive basis on Alizé Pharma's unacylated ghrelin (AZP-01) program for the treatment of Type II diabetes

27-Jan-2010 - Alizé Pharma, a group of companies developing innovative therapeutics for metabolic diseases and cancer, announced that Alizé Pharma SAS has entered into a research collaboration and license option agreement with Eli Lilly and Company regarding Alizé Pharma's AZP-01 program, a program focused on ...